NASDAQ:RLYB
Rallybio Corp
Rallybio Corp's revenue grew 34.9% in fiscal 2025 to $858,000 while operating margin rose to −3853.6%. The diluted share count rose 3.4%.Summary generated from Rallybio Corp's SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$858,000
Revenue growth+34.9%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−3853.6%
Net margin−1046.4%
ROICn/a
Return on equity−15.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+3.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 1 | 1 |
| Operating income | −46 | −68 | −79 | −60 | −33 |
| Net income | −47 | −67 | −75 | −58 | −9 |
| Free cash flow | −46 | −57 | −60 | −49 | n/a |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KDirector or officer change
Sep 9, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KEntry into a material agreement
Jun 1, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KTermination of a material agreement
May 4, 2026 - 8-KDirector or officer change
Mar 31, 2026